MARKET INSIGHTS

ZTOX Insights

AI-assisted articles on quarterly results, exchange filings, and earnings calls — tied to the companies you follow.

8 articles published

ZYDUSLIFE
ZYDUSLIFE
1 min read
Market Updates Corporate announcement

Zydus Lifesciences (ZYDUSLIFE): Company Update

Company Update Receipt of Warning Letter from USFDA for Baddi facility Receipt of Warning Letter from USFDA for Baddi facility Receipt of Warning Letter from USFDA for Baddi facility

Read article
ZYDUSLIFE
ZYDUSLIFE
1 min read
Market Updates Corporate announcement

Zydus Lifesciences (ZYDUSLIFE): Company Update

Company Update Receipt of Warning Letter from USFDA for Baddi facility Receipt of Warning Letter from USFDA for Baddi facility Receipt of Warning Letter from USFDA for Baddi facility

Read article
ZYDUSLIFE
ZYDUSLIFE
1 min read
Market Updates Corporate announcement

Zydus Lifesciences (ZYDUSLIFE): Buyback

Buyback Zydus Lifesciences Limited has informed the Exchange about Buyback Zydus Lifesciences Limited has informed the Exchange about Buyback Zydus Lifesciences Limited has informed the Exchange about Buyback

Read article
ZYDUSLIFE
ZYDUSLIFE
1 min read
Market Updates Corporate announcement

Zydus Lifesciences Announces Share Buyback via NSE Filing

Zydus Lifesciences Limited (NSE: ZYDUSLIFE) has notified the exchanges about a share buyback program. The announcement signals the pharma major's intent to return capital to shareholders.

Read article
ZYDUSLIFE
ZYDUSLIFE
1 min read
Market Updates Corporate announcement

Zydus Lifesciences (ZYDUSLIFE): Buyback

Buyback Zydus Lifesciences Limited has informed the Exchange about Buyback Zydus Lifesciences Limited has informed the Exchange about Buyback Zydus Lifesciences Limited has informed the Exchange about Buyback

Read article
ZYDUSLIFE
ZYDUSLIFE
1 min read
Market Updates Corporate announcement

Zydus Lifesciences (ZYDUSLIFE): Company Update

Company Update Zydus Therapeutics'' New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) granted Priority Review by the US FDA. Zydus Therapeutics'' New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) granted Priority Review by the US FDA. Zydus Therapeutics'' New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) granted Priority Review by the US FDA.

Read article
ZYDUSLIFE
ZYDUSLIFE
1 min read
Market Updates Corporate announcement

Zydus Lifesciences (ZYDUSLIFE): Press Release

Press Release Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 28, 2026, titled "Zydus Therapeutics New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) granted Priority Review by the US FDA". Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 28, 2026, titled "Zydus Therapeutics New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) granted Priority

Read article
ZYDUSLIFE
ZYDUSLIFE
1 min read
Market Updates Corporate announcement

Zydus Lifesciences Subsidiary Gets CGST Demand Order from Ahmedabad Authority

Zydus VTEC Limited, the wholly owned subsidiary of Zydus Lifesciences, has received a Demand Order-In-Original from the Deputy Commissioner of CGST & Central Excise based in Ahmedabad North Commissionerate.

Read article
MARKET INTELLIGENCE

Track Indian stocks with ZTOX AI

NSE & BSE filings, quarterly results, insider trades, and smart volume alerts — delivered on WhatsApp or Telegram. No separate app to install.

Free
Essential tracking to get started
₹0
  • Track 5 companies
  • News, NSE/BSE & insider alerts
  • Daily FII/DII activity
POPULAR
Basic
For active investors
₹89/mo
  • Track 20 companies
  • Everything in Free
  • Results, volume & live gainer alerts
Advanced
Deeper market signals
₹119/mo
  • Track 50 companies
  • Everything in Basic
  • Block deals & 60-day volume breakouts

Need more? Pro tracks up to 500 companies with preferential issue alerts.

Start free

No credit card required. Connect WhatsApp or Telegram in minutes.